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The Anorectic Effects of CRH and Restraint Stress 
Decrease with Repeated Exposures 
Dean D. Krahn, Blake A. Gosnell, and Mark J. Majchrzak 
Intracerebroventricular (icy) administration of corticotropin-releasing hormone (CRH) 
or exposure to a restraint stressor causes acute anorexia in rats. However, the elects 
on food intake of repeated injections of CRH or repeated exposures to restraint stress 
have not been previously reported. As the effects of these more chronic CRH and stress 
treatments may be of greater relevance to emerging hypotheses of the pathogenesis of 
human eating and affective disorders, we measured the changes in food intake and body 
weight of rats after repeated central injections of CRI-I. In two experiments using two 
different daily dosages of CRH and two different schedules of administration, we found 
that the anorectic effect of CRH decreased over repeated injections. Weight gain was 
slowed significantly only in the high-dose experiment. Rats may become tolerant to the 
anorectic effects of CRH delivered by repeated icy injections. These findings have im- 
portant implications for hypothesized mechanisms of anorexia nervosa and/or depression. 
Introduction 
The role of corticotropin-releasing hormone (CRH) in the endocrine and behavioral re- 
sponses to stressors has been the focus of intense research. Acute administration of CRH 
to rats causes not only release of adrenocorticotropic hormone (ACTH) and corticosterone 
(Rivier and Vale 1987), but also a behavioral syndrome similar to that caused by stressors. 
The CRH-induced behavioral changes include anorexia, increased grooming and activity, 
and decreased sexual receptivity (Sutton et al. 1982; Britton et al. 1982; Morley and 
Levine 1982; Sirinathsinghji et al. 1983). Pretreatment of rats with alpha-helical CRI-I 
(9-41), a competitive antagonist of CRH develeped by Rivier et al. (1984), prevents 
stress-induced anorexia (Krahn et al. 1986; Shibasaki et al. 1988) and the stress-induced 
inhibition of luteinizing hormone release (Rivier et al. 1986). Thus, CRH may be critical 
in the integration of endocrine and behavioral responses to stressors. 
The acute behavioral and endocrine changes in rats treated with CRH (icv) resemble 
the chronic symptom profile seen in patients with anorexia nervosa and/or depression 
(Gold et ai. 1986; Hotta et al. 1986). These patients also have elevated CRH levels in 
their cerebrospinal fluid (Gold et al. 1986; Hotta et al. 1986). The elevated CRI-I levels 
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in humans were noted by Gold et al. to be consistent with the hypothesis (suggested by 
others on the basis of animal data) that a hyperresponsive CRH system may mediate the 
hypothalamic-pituitary-adrenal abnormalities as well as the behavioral abnormalities pre- 
sent in these disorders (Gold and Rubinow 1987; Gold et al. 1987; Morley and Levine 
1982). However, the symptoms of artorexia nervosa patients are chronic and all the 
reported behavioral effects of CRH are acute, lasting only a few hours. 
In an attempt to correct this deficiency in the data base regarding the behavioral effects 
of CRH, we tested the effects on food intake and body weight of repeated icv injections 
of CRH in two different dosages and two different schedules. We also studied the effects 
of repeated exposure to restraint, a treatment we previously showed causes acute anorexia 
in rats through a CRH-mediated mechanism (Krahn et al. 1986; Shibasaki et al. 1988). 
We hypothesized that repeated treatments with CRH would result in decreasing anorectic 
effects, a change that would be consistent with the desensitization seen in the hypotha- 
lamic-pituitary-adrenal axis with chronic or repeated CRH or stressor treatments (Rivier 
and Vale 1984, 1987; Rivier and Plotsky 1986; Lima and Sourkes 1987). This result 
would not be consistent with the proposed mechanism for anorexia nervosa and melan- 
cholic depression which posits that repeated excessive secretion of CRH causes chronic 
anorexia and weight loss. We also predicted that the pattern of change in the anorectic 
response to repeated restraint treatments would resemble that seen with repeated CRH 
infusions. 
M e t h o d s  
Two experiments were performed on male Sprague-Dawley rats weighing 223-292 g at 
the time of surgery. The animals were housed individually in stainless steel cages with 
a reversed 12 hr light-12 hr dark cycle. In experiment 1, the light period was from 10 
PM to 10 AM; in experiment 2, the light period was from 8 PM to 8 AM. Food and water 
were available ad libitum (except where noted). Under sodium pentobarbital anesthesia 
(40-50 mg/kg), icy cannulas were implanted in the right lateral ventricle by methods 
similar to those previously reported (Gosne!! et al. 1987). Animals were allowed at least 
7 days to recover before testing began. 
Experiment 1 
Three groups of rats were treated once daily for 5 consecutive days. One group was given 
daily icy injections of CRH (5 ttg, 1.1 nmols; ovine CRH, Peninsula). CRH was dissolved 
in 0.9% saline (NaCI) and was delivered icy in a 5-lzl volume over 5-10 sex. In previous 
experiments, this dose consistently decreased food intake (Morley and Levine 1982). 
Injections were given at the beginning of the dark period. A second (control) group 
received dally icy injections of normal saline (NaCI). The third group was subjected to 
a daily 2-hr restraim period, a mild stressor which we have found to cause a short-term 
reduction in food intake (Krahn et al. 1986). The restraint stressor consisted of tightly 
wrapping the animals in disposable absorbant pads such that movement was prevented 
but breathing was not restricted. The restraint period began 2 hr before the beginning of 
the dark period; upon release from restraint, animals in this group were given icy injections 
of NaCl. Thus, all injections, release from restraint, and the start of food intake measux~,s 
coincided with the onset of the dark period. For all animals, food was not available for 
2 hr prior to the onset of the dark period° On each treatment day, f ~  in',ake was 
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determined by weight 2, 4, 12, and 22 hr following injections and was corrected for 
spillage at each measurement. Rats were weighed each day prior to treatment. 
Experiment 2 
Three groups of rats were given icy injections every 8 hr for 5 days. One group received 
CRH (1 Izg, 0.21 nmol) at every injection. The control group received NaCI at every 
injection. A third group received CRH (3 I~g, 0.64 nmol) in the first injection and NaCI 
in the remaining two injections. Thus, two groups received the same daily dose of CRH 
with different sche6ules: 1 ~g injected 3 times, 8 hr apart, or 3 Izg injected as a single 
bolus. Injection times corresponded to the onset of the dark period (8:00 AM), 8 hr ~:ter 
onset of the dark period, and 4 hr after the onset of the light period. Food intake was 
measured at 2, 4, 8, 16, and 24 hr after the onset of the dark period (the time of the 
initial injections). Body weights were measured daily 1 hr prior to onset of the dark 
period. 
Cannula placements and patencies were verified by observation of the drinking response 
to icy injections of 250 ng a~lgiotensin 1I (AH). AII was injected both before and after 
the experiments described above, and data from rats that did not begin drinking within 
3 min after injection on both occasions were excluded from data analysis. 
At each measure of food intake, cumulative intake data were analyzed with a two- 
factor analysis of variance (ANOVA): treatment × day. Within each treatment day, 
Dunnett's t-test (one-tailed) was used to compare mean intake of each treatment group 
to the mean intake of the corresponding control group. 
Results 
In experiment 1, there was a significant treatment effect on food intake measured at 2, 
4, and 12 hr after injection (Fz.,2 ffi 63.21, 38.69, and 4.59, respectively, all p ' s  < 
0.05). The trial factor (injection day) was significant at 2, 4, 12, and 22 hr (F4.ss -- 
3.55, 5.71, 21.43, and 16.36, respectively, all p 's  < 0.05). The treatment x day 
interaction was significant at 4 hr (F4.ss = 2.61, p < 0.05). Dunnett's t-tests indicated 
that CRH significantly reduced 2, 4, and 12 hr food intake on all 5 injection days. Total 
daily intake (22 hr) was significantly reduced on days 1, 2, and 5. Restraint stress also 
significantly reduced 2-hr intake on all 5 days. Four-hr intake was reduced by restraint 
on days 1, 2, 3, and 5. Twelve-hr cumulative intake was significantly reduced by restraint 
only on day 2. 
As Figure 1 suggests, the effect of CRH diminishes over treatment days. This sug- 
gestion is supported by a significant treatment x day interaction at 4 hr. When 4-hr 
intakes of the CRH group are converted to difference scores (g below the mean intake 
of controls) and analyzed with a one-factor ANOVA, there was a significant effect of 
injection day (F,,.32 = 6.22, p < 0.05). Dunnett's t-tests indicate that the reductions in 
intake on days 4 and 5 are significantly less than those observed on day 1. As can be 
seen in Figure 1, restraint was less potent and more variable in its effects on food intake, 
with the greatest effect observed on day 2. As with the CRH data, when restraint data 
are converted to difference scores and analyzed with an ANOVA, there was a significant 
effect of injection day (F4.32 = 8.25, p < 0.05). Post hoc tests for all pairwise comparisons 
indicated that the reduction due to restraint stress was greater on day 2 than on day 1, 
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Figure 1. Food intake (mean + SEM) measured 2, 4, 12, and 22 hr after daily icv injections of NaCI or 
CRH (5 itg) or 2-hr restraint. Injections and release from restraint occurred at the beginning of the dark 
period. *Significant differences from the corresponding control condition (p < 0.05, one-tailed Dunnett's 
test). 
and that the reductions on days 4 and 5 were less than on day 2 (Tukey's HSD test, 
p < 0.05). 
Changes in body weight are shown in Figure 2. When expressed as total gains (or 
losses) from initial body weight (day 1), there was a significant treatment effect (F2.22 
- 3.64) and a significant day effect (F4.ss = 44.49)(all p's < 0.05). After the second 
complete treatment day (days 3-6) ,  the mezn chan~e in weight for the CRH group was 
found to be significantly less than the change in control weight. Total change in weight 
for the restraint group differed from control only at the final measurement (day 6). At 
this time, control rats had gained an average of 14 _+ 4 g, restraint-treated rats had gained 
only 1 _+ 3 g, and CRlt-treated rats lost an average of 7 -+ 5 g. In terms of absolute 
body weight, there was a significant day effect and a significant treatment x day inter- 
action (FsjIo = 19.12 and Floj~o = 2.89, all p*s < 0.05); neither the CRH group nor 
the restraint group significantly differed from the control group on any day (Dunnett's t- 
tests). 
In experiment 2, there was a significant effect of treatment on 2- and 4-hr food intake 
(F2.2o = 17.13 and 5.52, p < 0.05). The day effect was significant at 2, 4, 8, and 24 
hr (F4.ao = 5.47, 8.54, 5.62, and 2.86, respectively, all p's < 0.05). The treatment x 
day interaction was significant at 2 and 16 hr (F8.8o - 5.27 and 2.47, p < 0.05) and 
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Figure 2. Top: Changes in body weights (mean -+ SEM) after daily treatments with NaCI, CRH 
(5 I~g) or restraint stress. Initial mean weights for NaCI, restraint, aad CRH groups were 299 -+ 
8 g, 307 .4- 6 g, and 309 .4- 3 g. Bottom: Changes in body weights after daily icy injections o f  
NaCI or CRH (3 p,g) given either in three equally spaced 1-1xg injections (1 p,g x 3, or as a single 
3-1xg injection. Initial mean weights for NaCI, CRH 1 p.g × 3, and CRH 3 Ixg groups were 306 
-- 6g, 308"4- 5g, and 307 -+ 6 g. 
approached significance at 4 and 8 hr (0.05 < p < 0.10). As shown in Figure 3, both 
CRH treatments reduced 2-hr intake only on days 1-3. Four-hour intake was reduced on 
days 1-3 in the group receiving the single 3-p,g injection of CRH and only on days 1 
and 2 in the group receiving 1 p~g of CRH three times daily. By days 4 and 5 neither 
treatment resulted in significant reductions in food intake. Total daily intakes, body 
weights, and body weight changes of the three groups did not differ on any treatment 
day. 
For each treatment group, data were expressed as differences from control, and ana- 
lyzed with one-factor ANOVAs. Dunnett's t-tests indicated that at 2 hr, both treatments 
reduced intake less on days 3, 4, and 5 than on day I. By 4 hr, only the reductions on 
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Figure 3. Food intake (mean + SEM) measured 2, 4, 16, and 24 hr after daily icy injections of NaC1 or 
CRH (3 ~g) given either in three equally spaced l-I~g injections (l-p.g x 3) or as a single 3-~g injection. 
*Significant differences from the corresponding control condition (p < 0.05, one-tailed Dunnett's t-test). 
Discussion 
The major finding in the two experiments described above is that repeated central CRH 
injections resulted in progressively smaller decreases in food intake comp~ed with saline 
injections. Restraint did not result in decreases in food intake as large as those caused 
by icy CRH injections, although the reductions were significant. Also, the observed 
pattern of change in the magnitude of the anorectic effect of restraint over repeated 
treatments was less consistent than that seen in the CRH-treated rats. The decrease in 
the magnitude of CRH effects with repeated administration could be the result of changes 
in the number or affinity of CRH receptors (i.e., tolerance or down-regulation). On the 
other hand, other types of behavioral adap~tions not directly involving CRH receptor 
changes could be involved. 
The failure to observe an adaptation to the effects of restraint is probably due in large 
part to the lack of a large effect on the first exposure. Variability in the response to 
restraint may be due to variations in applying the restraint stressor (e.g., tightness, limb 
position), factors which do not apply to CRH administrations. However, in general, the 
tendency seen in these experiments was that restraint caused slightly less suppression in 
food intake in later trials and no significant decrement in body weight. Thus, these results 
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again provide data showing that one cannot predict from acute behavioral effects of 
stressors or neurochemicals what the effects of chronic stressor or neurochemical treatment 
will be. 
In experiment 1, the 5-~g (1.1 nmols) daily dose of CRH caused a slowing of weight 
gain. Though this may be construed as being consistent with the hypothetical patho- 
physiology of anorexia nervosa or depression, it is important to note that after the losses 
following the first treatment day, weight gain resumed. Our results contrast with those 
of Arase et al. (1988) who reported that a similar daily dose (4.8 p.g) of CRH delivered 
continuously at a rate of 0.2 p,g/hr into the third ventricle resulted in progressive decreases 
in body weight over 7 days of treatment. Arase et al. also reported that a similar, chronic, 
central CRH infusion resulted in oagoing weight loss in genetically obese Zucker rats, 
although in this experiment the lean controls showed no significant decrease in food intake 
at any point in the experiment (Arase et al. 1989). Hotta (1989) confirmed that a significant 
decrement in weight gain occurred in rats treated with 7 days of continuous, central CP, H 
infusion (24 I~g/day) when compared with saline-treated rats. Even with this high dose 
of CRH, Hotta found a lessening of the anorectic effect of CRH over extended usage. 
In contrast to these studies, Rohner-Jeanrenaud et al. (1989), using a continuous central 
infusion of CRH, did not show a decrement in the weight of lean animals, although 
weight gain was decreased in genetically obese rats. The differences between our study 
and these chronic studies may be related to differences in the site of injection (lateral 
versus third ventricle), doses of CRH, or in the ability of intermittent versus continuous 
CRH administration to induce behavioral adaptation. The results of most of the continuous 
infusion studies, taken together with ours, suggest that the effects of CRH treatment on 
weight involves both behavioral and metabolic changes. Behavioral adaptation to repeated, 
intermittent CRH (icy) administration has been demonstrated in the pigeon (Lei et al. 
1988). It is possible that intermittent CRH administration allows learning of adaptive 
behavioral responses to future CRH treatments that is less likely under conditions of 
constant exposure to CRH. 
As we do not have data on the cortisol or norepinephrine levels in these animals, we 
are unable to ascertain whether this behavioral adaptation was accompanied by similar 
adaptations in the neuroendocrine and/or autonomic responses to CRH. However, others 
have shown that similar decrements in the size of neuroendocrine responses to CRH do 
occur (see Rivier and Vale 1984, 1987; Rivier and Plotsky 1986; Lima and Sourkes 
1987), thus providing further support for the hypothesis that the decreased behavioral 
effect of CRH (and perhaps of stressors) is due to a CRH system-specific adaptation. 
Obviously, the best evidence for a CRH-specific adaptation would be the demonstration 
of down-regulation of CRH receptors. This down-regulation has been demonstrated in 
response to previous CRH administration (Reisine and Hoffman 1983; Rivier and Plotsky 
1986; Holmes et al. 1984). Down-regulation was also observed in response to chronic 
stress (round-the-clock intermittent foot shock) in the frontal cortex and anterior pituitary 
after 3 days and in the hypothalamus after 14 days (Kant et al. 1988). Unfortunately, 
behavioral correlates of this down-regulation are unknown. 
It is unclear whether the chronic continuous administration paradigm of Arase et al. 
(1988) and Rohner-Jeanrenaud et al. (1989) or the intermittent administration paradigm 
of the present study is of greater relevance for the hypothesis regarding the role of CRH 
hyperresponsiveness in psychopathology. It is clear that different schedules of adminis- 
tration result in markedly different effects on feeding and weight in rats and that these 
complicated effects will need to be acknowledged in more refined, future hypotheses. 
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The failure to demonstrate that intermittent CRH administration causes ongoing anorexia 
and weight loss does not mean that the CRH system is uninvolved in anorexia nervosa, 
but it does suggest that intermittent CRH elevations by themselves are insufficient to 
cause the anorexia-like syndrome in normal animals. It may be that anorectic patients 
differ from normals by being unable to adapt to CRH elevations or by having deficits in 
other neural systems (e.g., vasopressin system abnormalities) which potentiate the effects 
of CRH system abnormalities (Ebert et al. 1984). Finally, it is possible that the high 
CRH levels in the cerebrospinal fluid of anorexia nervosa patients do not cause behavioral 
changes, but are secondary effects of starvation. 
Refe rences  
Arase K, Shargill N$, Bray GA (1989): Effec~ of corticotropin-releasin~ factor on genetically 
obese (fatty) rats. Physiol Behav 45:565-570. 
Arase K, York DA, Shimizu H, Shargill N, Bray GA (1988): Effects of cortiooffopin-releasing 
factor on food intake and brown adipose tissue thermogenesis in rats. Am J Physiol 193:E255- 
E259. 
Britton DR, Koob GF, Rivier J, Vale W (1982): Intraventricular corticotropin-releasing factor 
enhances behavioral effects of novelty. Life Sci 31:363-367. 
Ebert MH, Kaye WK, Gold PW (1984): Neurotransmitter metabolism in anorexia nervosa. In Pirke 
KM, Ploog D (eds), The Psychobiology of Anorexia Nervosa. Berlin and Heidelberg: Springer- 
Verlag, pp 58-72. 
Gold PW, Gwirtsman H, Avgerinos PC, et al (1986): Abnormal hypothalamic-pituitary-adrenal 
function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected 
patients. N Engl J Med 314:1335-1342. 
Gold PW, Kling MA, Kellner CH, et al (1987): Corticotropin releasing hormone: Relevance to 
normal physiology and to the pathophysiology of depression and anorexia nervosa. In Halbreich 
U (ed), Hormones and Depression. New York: Raven Press, pp 77-89. 
Gold PW, Rnhinow DR (1987): Neuropeptide function in affective illness: Corticotropin-releasing 
hormone and somatostatin as model systems. In Meltzer HY (ed), Psychopharmacology: The 
Third Generation of Progress. New York: Raven Press, pp 617-627. 
Gosnell BA, Grace M, Levine AS (1987): Effects of [3-chlomaltrexamine on food intake, body 
weight and opioid-induced feeding. Life Sci 40:1459-1467. 
Holmes M, Antoni F, Szentiendrei T (1984): Pituitary receptors for corticotropin-releasing factor: 
No effect of vasopressin on binding or activation of adenylate cyclase. Neuroendocrinology 
39:162-169. 
Hotta M (1989): The effects of long-term intracerebroventricular administration of corticotropin- 
releasing factor on food intake, body weight and hypothalamic-pituitary-adrenal hormones (Ab- 
stract 1737). Proc Endocrinol Soc p 457. 
Hotta M, Shibasaki T, Masuda A, et al (1986): The responses of plasma adrenocorticotropin and 
cortisol to corticotropin-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH 
in anorexia nervosa patients. J Clin Endocrinol Metab 62(2):319-324. 
Kant GJ, Anderson SM, De Souza EB (1988): Effects of chronic stress on brain and pituitary 
corticotropin-releasing factor receptors (Abstract). Soc Neurosci 14:668. 
Krahn DD, Gosnell BA, Grace M, Levine AS (1986): CRF antagonist partially reverses CRF- and 
stress-induced behavioral effects. Brain Res Bull 17:285-289. 
Lei A, Ahlers ST, WojniclO FHE, Harrod C, Barrett IE (1988): Effects of central administration 
of corticotropin-releasing factor (CRF) on schedule-controlled responding and central mono- 
aminergic metabolites in pigeons (Abstract 7393). Fed Proc. 
Lima L, Sourkes TL (1987): Effect of corticotropin-releasing factor on adrenal DBH and PNMT 
activity. Peptides 8:437-441. 
1102 BIOL PSYCHIATRY D.D. Krahn et al. 
1990;27:1094-1102 
Morley JE, Levine AS (1982): Corticotropin-releasing factor, grooming and ingestive behaviors. 
Life Sci 31:1459-1464. 
Morley JE, Levine AS, Willenbring ML (1986): Stress-induced feeding disorders. In Carruba MO, 
BlundeU JE (eds), Pharmacology of Eating Disorders: Theoretical and Clinical Developments. 
New York: Raven Press, pp 71-99. 
Reisine T, Hoffman A (1983): Desensitization of corticotropin-releasing factor receptors. Biochem 
Biophys Res Comm 111:919-~25. 
Rivier C, Plotsky PM (1986): Mediation by corticotropin-releasing factor (CRF) of adenohypo- 
physial hormone secretion. Ann Rev Physiol 48:475-494. 
Rivier C, Rivier J, Vale W (1986): Stress-induced inhibition of reproductive function: Role of 
endogenous corticotropin-releasing factor. Science 231:607-609. 
Rivier C, Vale W (1984): Effect of the long-term administration of corticotropin-releasing factor 
on the pituitary-adrenal and pitvitary-gonadal axis in the male rat. J Clin Invest 75:689-694. 
Rivier C, Vale W (1987): Influence of the frequency of ovine corticotropin-releasing factor admin- 
istration on adrenocorticotropin and corticostemne secretion in the rat. Endocrinology 113(4):1422- 
1426. 
Rivier J, Rivier C, Vale W (1984): Synthetic competitive antagonists of corticotmpin-releasing 
factor: Effect on ACTH secretion in the rat. Science 224:889-891. 
Rohner-Jeanrenaud F, Walker CD, Greco-Perotto R, Jeanrenaud B (1989): Central corticotropin- 
releasing factor administration prevents the excessive body weight gain of genetically obese 
ffa/fa } rats. Endocrinology 124:733-739. 
Shibasaki T, Yamauchi N, Kato Y, et al (1988): Involvement of corticotropin-releasing factor in 
restraint stress-induced anorexia and reversion of the anorexia by somatostatin in the rat. Life 
Sci 43:1103-1110. 
Skinathsinghji DJS, Rees LH, Rivier J, Vale W (1983): Corticotropin-releasing factor is a potent 
inhibitor of sexual receptivity in the female rat. Nature 305:232-235. 
Sutton RE, Koob GF, LeMoal M, Rivier J, Vale W (1982): Corticotropin-releasing factor produces 
behavioral activation in rats. Nature 297:331-333. 
